HEALTH House International Ltd (ASX:HHI) has announced the commencement of a non- interventional observational study in Germany examining the effect of its own-branded cannabis extracts on quality of life of patients and their safety and tolerability.
The study has been launched by CanPharma (Germany) and supported by Kalapa Clinic (Germany/Spain), both 100% owned by Health House.
The results from the 600-patient study will assist in improving the knowledge and confidence of medical professionals when prescribing cannabis extracts, which is key to the Company ́s growth strategy in the German market.
“As a leader in the field of medicinal cannabis, we recognise that due to the limited historical data currently available on the medical use of cannabis, practitioners face uncertainty when it comes to prescribing.
“Optimal patient care needs medical progress as well as professional education. In cooperation with leading experts, CanPharma is working to advance the clinical evidence for the use and effectiveness of cannabis-based medicines” , said David Attwood, CEO of Health House.
The open, prospective, non-interventional study using CanPharma ́s own-brand full-spectrum cannabis extracts starts now and will run for two years, with the first interim results expected in approximately six months.
The analysis of data sets collected from patients will support treatment safety as well as the ongoing improvement and standardisation of individualised cannabinoid therapy.
The individual observation period for each participant is six months. CanPharma’s observational study will be conducted at various centres in Germany.
“Cannabis treatment must be tailored to the individual needs of patients,” says Dr Henrik Sprengel, Executive Director of Health House and CEO of CanPharma.
“Gaining knowledge about the safety and tolerability of our cannabis extracts under everyday conditions is an important task that will drive confidence of medical professionals in prescribing. We are pleased and proud to be doing pioneering work here and to be driving the acquisition of scientific data.”
The observational study is being conducted by Kalapa Clinic, an independent part of the Health House group, whose medical experts have years of experience and in-depth expertise in cannabis therapy.
Kalapa was the first medical cannabis counselling centre to be established in Europe. It advises health professionals and patients on the appropriate use of cannabis-based medicines for the treatment of various indications.
About Health House
Health House International and the entities it controls (the Group) is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.
The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia.
In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.
The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.
For more information, please visit www.healthhouse.com.au
